European Medicines Evaluation Agency Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation for Lux Biosciences’ LX211 for the Treatment of Uveitis

JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the EMEA committee for Orphan Medicinal Products has adopted a positive opinion on orphan medicinal product designation for the company’s investigational therapeutic, LX211, for the treatment of chronic, non-infectious uveitis. LX211 is a next-generation calcineurin inhibitor intended for the treatment of non-infectious posterior, intermediate and panuveitis (an autoimmune disease characterized by chronic inflammation of the eye).

MORE ON THIS TOPIC